Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Capital Expenditures (2017 - 2021)

Rein Therapeutics filings provide 4 years of Capital Expenditures readings, the most recent being $5000.0 for Q3 2021.

  • For the quarter ending Q3 2021, Capital Expenditures changed N/A year-over-year to $5000.0, compared with a TTM value of $157000.0 through Dec 2021, up 685.0%, and an annual FY2021 reading of $157000.0, up 3040.0% over the prior year.
  • Capital Expenditures hit $5000.0 in Q3 2021 for Rein Therapeutics, down from $67000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $2.3 million in Q3 2018, with the low at $4000.0 in Q2 2019.
  • Median Capital Expenditures over the past 4 years was $38000.0 (2017), compared with a mean of $324866.7.
  • The sharpest move saw Capital Expenditures surged 8337.04% in 2018, then tumbled 99.78% in 2019.
  • Year by year, Capital Expenditures stood at $68000.0 in 2017, then soared by 2741.18% to $1.9 million in 2018, then tumbled by 99.22% to $15000.0 in 2019, then plummeted by 66.67% to $5000.0 in 2021.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $5000.0, $67000.0, and $85000.0 for Q3 2021, Q2 2021, and Q1 2021 respectively.